These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 36719099)

  • 1. TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer.
    Karahan ZS; Aras M; Sütlü T
    Turk J Haematol; 2023 Feb; 40(1):1-10. PubMed ID: 36719099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer.
    Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki AM; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
    Eur J Immunol; 2019 Aug; 49(8):1278-1290. PubMed ID: 31054264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
    Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
    Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A TCR-based Chimeric Antigen Receptor.
    Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
    Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.
    Knies D; Klobuch S; Xue SA; Birtel M; Echchannaoui H; Yildiz O; Omokoko T; Guillaume P; Romero P; Stauss H; Sahin U; Herr W; Theobald M; Thomas S; Voss RH
    Oncotarget; 2016 Apr; 7(16):21199-221. PubMed ID: 27028870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells.
    Zhuang X; Long EO
    Front Immunol; 2022; 13():840844. PubMed ID: 35585985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells.
    Kath J; Franke C; Drosdek V; Du W; Glaser V; Fuster-Garcia C; Stein M; Zittel T; Schulenberg S; Porter CE; Andersch L; Künkele A; Alcaniz J; Hoffmann J; Abken H; Abou-El-Enein M; Pruß A; Suzuki M; Cathomen T; Stripecke R; Volk HD; Reinke P; Schmueck-Henneresse M; Wagner DL
    Blood; 2024 Jun; 143(25):2599-2611. PubMed ID: 38493479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
    Sharma P; Kranz DM
    Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7
    Zhuang X; Long EO
    Cancer Immunol Res; 2019 Jun; 7(6):939-951. PubMed ID: 31018957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
    Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
    J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3ζ -engineered NK cells mediates antitumor effects.
    Li S; Zhang C; Shen L; Teng X; Xiao Y; Yu B; Lu Z
    Cancer Immunol Immunother; 2023 Mar; 72(3):769-774. PubMed ID: 35988132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of CAR-NK Cells Targeting cSCC-Specific Antigens for Precision Immunotherapy.
    Tayanloo-Beik A; Roudsari PP; Aghayan H; Arjmand R; Rezaei-Tavirani M; Larijani B; Rajaeinejad M; Mosaed R; Arjmand B
    Methods Mol Biol; 2024; 2849():253-263. PubMed ID: 38095836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4.
    Jamali A; Hadjati J; Madjd Z; Mirzaei HR; Thalheimer FB; Agarwal S; Bonig H; Ullrich E; Hartmann J
    Front Immunol; 2020; 11():2028. PubMed ID: 32983147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.